|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Cancer Institute (NCI) |
|---|---|
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00086853 |
Purpose
RATIONALE: Tariquidar may reduce tumor-cell resistance to chemotherapy drugs and allow the tumor cells to be killed. Positron emission tomography (PET) imaging using technetium Tc 94m sestamibi and tariquidar may improve the ability to detect the retention of chemotherapy drugs in cancer cells and allow doctors to plan more effective treatment.
PURPOSE: This diagnostic trial is studying PET imaging using tariquidar and technetium Tc 94 sestamibi to see how well it works in detecting the retention of chemotherapy drugs in the tumor cells of patients with cancer.
| Condition | Intervention |
|---|---|
|
Unspecified Adult Solid Tumor, Protocol Specific |
Drug: tariquidar Drug: technetium Tc 94m sestamibi Procedure: positron emission tomography Procedure: radionuclide imaging |
| Study Type: | Interventional |
| Study Design: | Diagnostic |
| Official Title: | A Pilot Study of Tc-94m Sestamibi PET MDR Imaging |
| Estimated Enrollment: | 15 |
| Study Start Date: | May 2004 |
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a pilot study.
Patients receive technetium Tc 94m sestamibi IV and concurrently undergo positron-emission tomography (PET) scanning. After at least 72 hours, patients receive tariquidar IV over 30-45 minutes. Within 1-4 hours after tariquidar administration, patients undergo an additional PET scan using technetium Tc 94m sestamibi.
Patients are followed for 1 month.
PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study within 15 months.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of cancer
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Contacts and Locations More Information
| Study ID Numbers: | CDR0000371645, NCI-04-C-0177 |
| Study First Received: | July 8, 2004 |
| Last Updated: | December 13, 2008 |
| ClinicalTrials.gov Identifier: | NCT00086853 |
| Health Authority: | United States: Food and Drug Administration |
|
unspecified adult solid tumor, protocol specific |
